Impact of Nebivolol on Central Aortic Pressure

This study has been withdrawn prior to enrollment.
(Similar study already published)
Sponsor:
Information provided by:
Creighton University
ClinicalTrials.gov Identifier:
NCT01051947
First received: January 19, 2010
Last updated: July 29, 2011
Last verified: July 2011
  Purpose

A randomized, cross-over, single-blind study to compare the effects of nebivolol and metoprolol on central aortic pressure and peripheral brachial pressure in patients with stable cardiovascular disease.


Condition Intervention
Central Aortic Pressure
Drug: Nebivolol
Drug: Metoprolol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Impact of Nebivolol on Central Aortic Pressure

Resource links provided by NLM:


Further study details as provided by Creighton University:

Primary Outcome Measures:
  • Stable blood pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Subjects will be randomized to nebivolol or metoprolol. Their medication will be titrated so that their blood pressure is within 10% of their initial reading.


Enrollment: 0
Study Start Date: December 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nebivolol
Nebivolol therapy for 2-6 weeks depending on blood pressure readings
Drug: Nebivolol
10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
Experimental: Metoprolol
Metoprolol therapy for 2-6 weeks depending on blood pressure readings
Drug: Metoprolol
dosage prescribed prior to starting on study

  Eligibility

Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with history of hypertension
  • Subjects who have received metoprolol for a minimum of 3 months

Exclusion Criteria:

  • Patients who have had an acute myocardial infarction, coronary revascularization or who have been hospitalized for heart failure or cardiac arrhythmia in the past 6 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01051947

Locations
United States, Nebraska
The Cardiac Center at Creighton University
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Creighton University
Investigators
Principal Investigator: Jennifer Campbell, PharmD Creighton University
  More Information

No publications provided

Responsible Party: Jennifer Campbell, PharmD, Creighton University
ClinicalTrials.gov Identifier: NCT01051947     History of Changes
Other Study ID Numbers: 08-15168
Study First Received: January 19, 2010
Last Updated: July 29, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Creighton University:
Nebivolol
Metoprolol
central aortic pressure
hypertension

Additional relevant MeSH terms:
Metoprolol
Nebivolol
Metoprolol succinate
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents

ClinicalTrials.gov processed this record on April 17, 2014